Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics.
Antibody-drug conjugate specialist TORL has raised $158 million in a Series B2 financing, led by Deep Track Capital, bolstering its cash reserves as it tries to advance a raft of ADC candidates through clinical testing.
